Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Trial
Official title:
A Phase Ib Study of APL-1202 in NMIBC Patients Who Are Resistant to One Induction Course of BCG Treatment
A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.
Six eligible participants will be administered with APL-1202 one week prior to the first BCG instillation, during the six-week course of BCG instillation, and additional five weeks, for a total of 12 weeks of dosing. Safety assessment will be performed during the entire 13 week study duration. Plasma and urine samples will be collected from each participant at prior to first and fifth BCG instillations for PK analysis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT03839472 -
Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors
|
N/A | |
| Recruiting |
NCT04179162 -
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
|
Phase 1/Phase 2 | |
| Terminated |
NCT03719300 -
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
|
Phase 2 | |
| Terminated |
NCT03167151 -
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03148158 -
Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident
|
N/A | |
| Terminated |
NCT06069453 -
Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.
|
N/A | |
| Completed |
NCT02009332 -
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05176145 -
Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test
|
N/A |